Literature DB >> 19887572

Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes.

Gabriele Tiller1, Pamela Fischer-Posovszky, Helmut Laumen, Andreas Finck, Thomas Skurk, Michaela Keuper, Ulrich Brinkmann, Martin Wabitsch, Dieter Link, Hans Hauner.   

Abstract

Expansion of adipose tissue mass by hypertrophy and hyperplasia is the hallmark of obesity. An automated cDNA screen was established to identify secreted human proteins with an inhibitory effect on adipocyte differentiation and, thereby, a potential inhibitory effect on adipose tissue growth. A member of the TNF superfamily, TNF-like weak inducer of apoptosis (TWEAK; TNF superfamily 12) was identified by means of high-throughput screening with the lipophilic dye Nile Red as an inhibitor of murine adipocyte differentiation and, subsequently, also of human adipocyte differentiation. TWEAK inhibited lipid deposition in a dose-dependent manner without causing cytotoxic effects. This inhibitory action was mimicked by an agonistic antibody of the TWEAK receptor. The TWEAK receptor (fibroblast growth factor inducible 14; CD266) was expressed on human primary preadipocytes and mature adipocytes. Knockdown of TWEAK receptor by short-hairpin RNA abolished the inhibitory effect of TWEAK on cell differentiation, demonstrating that the effects of TWEAK are mediated by its specific receptor. Inhibition of differentiation was the result of interference at an early step of transcriptional activation as assessed by decreased peroxisome proliferator-activated receptor-gamma, CCAAT enhancer-binding protein alpha (C/EBPalpha), and CCAAT enhancer-binding protein beta (C/EBPbeta) mRNA expression. In contrast to TNFalpha, basal and insulin-stimulated glucose uptake and lipolysis of terminally differentiated mature adipocytes and secretion of proinflammatory cytokines were not altered in the presence of TWEAK, and nuclear factor kappa B activity was only weakly induced. We conclude from our findings that TWEAK and the corresponding agonistic antibody have the potential to prevent adipose tissue growth without adversely influencing central metabolic pathways or proinflammatory cytokine secretion in adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887572     DOI: 10.1210/en.2009-0488

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

1.  miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression.

Authors:  Eun Kyung Lee; Mi Jeong Lee; Kotb Abdelmohsen; Wook Kim; Mihee M Kim; Subramanya Srikantan; Jennifer L Martindale; Emmette R Hutchison; Hyeon Ho Kim; Bernard S Marasa; Roza Selimyan; Josephine M Egan; Steven R Smith; Susan K Fried; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2010-12-06       Impact factor: 4.272

Review 2.  20 Years with SGBS cells - a versatile in vitro model of human adipocyte biology.

Authors:  Daniel Tews; Rolf E Brenner; Reiner Siebert; Klaus-Michael Debatin; Pamela Fischer-Posovszky; Martin Wabitsch
Journal:  Int J Obes (Lond)       Date:  2022-08-19       Impact factor: 5.551

3.  Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk.

Authors:  Andrés Díaz-López; Mònica Bulló; Matilde R Chacón; Ramón Estruch; Joan Vendrell; Javier Díez-Espino; Montserrat Fitó; Dolores Corella; Jordi Salas-Salvadó
Journal:  Cardiovasc Diabetol       Date:  2014-02-24       Impact factor: 9.951

Review 4.  TWEAK: A New Player in Obesity and Diabetes.

Authors:  Joan Vendrell; Matilde R Chacón
Journal:  Front Immunol       Date:  2013-12-30       Impact factor: 7.561

5.  Deletion of TNF-like weak inducer of apoptosis (TWEAK) protects mice from adipose and systemic impacts of severe obesity.

Authors:  Grace Bennett; Katherine J Strissel; Jason DeFuria; Junpeng Wang; Dayong Wu; Linda C Burkly; Martin S Obin
Journal:  Obesity (Silver Spring)       Date:  2014-03-08       Impact factor: 5.002

6.  TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors.

Authors:  Verena Zoller; Jan-Bernd Funcke; Michaela Keuper; Muad Abd El Hay; Klaus-Michael Debatin; Martin Wabitsch; Pamela Fischer-Posovszky
Journal:  Cell Death Dis       Date:  2016-10-13       Impact factor: 8.469

Review 7.  Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.

Authors:  Xavier Escoté; Saioa Gómez-Zorita; Miguel López-Yoldi; Iñaki Milton-Laskibar; Alfredo Fernández-Quintela; J Alfredo Martínez; María J Moreno-Aliaga; María P Portillo
Journal:  Int J Mol Sci       Date:  2017-08-15       Impact factor: 5.923

8.  Tumor Necrosis Factor-like Weak Inducer of Apoptosis: A Novel Serum Marker in Patients with Severe Alopecia.

Authors:  Abdul-Aziz Ibrahim Al Taweel; Ahmed Mohamed Hamed; Amira Mohamed Noureldin Abdelrahman; Mona Nady Ibrahim Hassan
Journal:  Int J Trichology       Date:  2019 May-Jun

9.  Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.

Authors:  Ana Belen Sanz; Maria Dolores Sanchez-Niño; Susana Carrasco; Felix Manzarbeitia; Olga Ruiz-Andres; Rafael Selgas; Marta Ruiz-Ortega; Carmen Gonzalez-Enguita; Jesus Egido; Alberto Ortiz
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

Review 10.  Role of the TWEAK-Fn14-cIAP1-NF-κB Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis.

Authors:  Emeka K Enwere; Eric C Lacasse; Nadine J Adam; Robert G Korneluk
Journal:  Front Immunol       Date:  2014-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.